New York, USA – June 28, 2022 – Cancer immunotherapy has made remarkable progress in the past decade. Among different therapy types, bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-based targeted cancer immunotherapy. So far, BsAbs drugs have been proved clinically effective and approved for the treatment of hematologic malignancies, and numerous drugs of this type for solid tumors are now undergoing evaluation in clinical trials.
Drawing upon years’ experience serving the antibody research community, Creative Biolabs now introduces the one-stop BsAb manufacturing service supported by advanced approaches including hybrid-hybridoma technology, chemical conjugation, and genetic methods using recombinant DNA technology.
Creative Biolabs provides BsAb manufacturing services by utilizing hybrid-hybridoma technology, also known as quadroma approach. The expert team is skillful in using hybridoma cell lines from two different species to establish production cell lines in order to reduce the Ig heavy chains and light chains mispairing, and is capable of sensitive and fast screening assay of the hybrid hybridoma culture medium to ensure BsAb targeting affinity.
Chemical conjugation is also a frequently-used method among projects Creative Biolabs has managed. The scientists are confident to guide clients from choosing mAbs and antibody fragments, designing a conjugation strategy, to scale-up production, purification, and characterization. The chemical crosslinkers are of a wide coverage, including but not limited to hetero-bifunctional chemical crosslinkers (SPDP/DTT, Traut’s reagent/SMCC), homo-bifunctional chemical crosslinkers (DTNB, PDM), and any special linkers provide by clients.
Creative Biolabs also offers the custom BsAb generation by genetic engineering, enabling clients to adjust the format, size, valency, flexibility, and half-life of BsAb to achieve the desired BsAb profile. The experts are committed to offering a suitable strategy to meet the unique requirements of every customer through a variety of techniques, such as knobs-into-holes (KIH), charge pair, etc.
“We truly appreciate the critical role that global scientists and their products play in global health issues and hope to facilitate their way to scientific innovation and discovery. BsAbs have shown high potential in tumor treatment, and that’s why we built a low-cost, high-yield, and time-efficient platform for BsAb manufacturing with the flexibility of creating various BsAb products for both academic and industrial applications,” said a scientist from the BsAb team at Creative Biolabs.
More information can be found at https://www.creative-biolabs.com/BsAb.
About Creative Biolabs
Creative Biolabs has been dedicated to offering services on antibody discovery, engineering, production, and analysis for years. The bispecific antibody (BsAb) team has gathered a collective of experienced scientists committed to providing high-quality services to customers all over the world, covering BsAb design, purification, engineering, manufacturing, and BsAb analysis service.